Arthritis is two different diseases, and we treat each one differently.
In osteoarthritis, cartilage breaks down under years of load and inflammation feeds the cycle. In rheumatoid and psoriatic arthritis, the immune system attacks the joint lining itself. The pain feels similar, but the biology differs.
The biology decides the delivery. A worn joint receives cells injected directly into the joint capsule under image guidance. Systemic autoimmune disease receives cells by IV infusion, to calm the immune response body-wide.
We treat osteoarthritis and inflammatory arthritis.
The protocol depends on the diagnosis. The final prescription is always the physician's, after your imaging, labs, and history are reviewed.
Wear & degeneration
Osteoarthritis
Knee, hip, shoulder, ankle, and small-joint OA with imaging-confirmed cartilage loss but preserved joint space. Cells are injected directly into the affected joint under ultrasound or fluoroscopy. The procedure is completed in a single day and requires no general anesthesia. The strongest evidence is in early to moderate disease (Kellgren‑Lawrence 1–3), where there is still cartilage to preserve.
UC‑MSC 20–60M per joint · intra-articular · PRP combosImmune-driven
Inflammatory & Autoimmune
Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Sjögren's. Because the disease is systemic, the cells are delivered by IV infusion, which helps calm an overactive immune response and ease joint pain, swelling, and morning stiffness. The therapy complements your rheumatologist's DMARDs or biologics rather than replacing them, and is offered to patients whose systemic disease is controlled.
UC‑MSC 50M or 100M · IV systemic · Muse cell optionArthritis, joint by joint.
The arthritic conditions we treat in each region, and every protocol we run for them. Your physician sets the final prescription after reviewing your imaging and labs.
No match for that term. Try the joint’s name instead, or ask a physician directly — this list covers the most common arthritic indications, not every one.
Doses run from 20 to 100 million cells.
Every dose is expanded from Wharton's jelly umbilical-cord tissue, tested for viability, and scaled to the joint — or the immune burden — being treated.
20–60M
cells per joint for osteoarthritis — 20–30M for mild disease, 40–60M for moderate — placed intra-articularly under image guidance.
50–100M
cells by IV infusion for rheumatoid, psoriatic, and other inflammatory arthritis — 50M standard, 100M high-dose protocols.
ISO‑certified
GMP laboratory. Each dose is released only after sterility, identity, and viability verification.
What happens inside the joint.
Tap a step to follow the cells into the joint.
What recovery looks like.
A typical single-joint timeline. Your physician tailors it to your joints and your diagnosis.
Day 0
Same-day procedure
A 30–60 minute visit: exam, image-guided injection or IV infusion, brief observation. Local anesthesia; sedation not typically required.
First 72 hours
Light activity
Mild soreness or swelling at the injection site usually resolves within 48–72 hours. Acetaminophen preferred over NSAIDs in this window.
Weeks 4–6
Initial response
Many patients notice the first change in pain or stiffness here. Aftercare check-ins at 2 and 6 weeks track progress.
Months 3–6
Peak benefit
Gains continue as the joint environment stabilizes. Trial data show benefits sustained at 12 months for many patients.
The evidence, briefly.
Three anchor findings from the peer-reviewed arthritis literature.
RCT
Allogeneic MSCs beat hyaluronic acid on pain and function in knee osteoarthritis, with gains maintained at 12 months.
Vega A, et al. Transplantation, 2015.
UC‑MSC
Randomized Phase I/II trial: repeated umbilical-cord MSC dosing outperformed a single dose and hyaluronic acid for knee OA.
Matas J, et al. Stem Cells Transl Med, 2019.
2,372
patients in the largest published safety analysis of stem cell therapy for orthopedic conditions: low adverse event rate, most events transient and self-limited.
Centeno CJ, et al. Int Orthop, 2016.
The evidence is encouraging and growing, but it is stronger for osteoarthritis than for inflammatory arthritis, and none of it guarantees a result for any individual. MSCs do not, in the imaging sense, regrow cartilage — end-stage bone-on-bone disease is usually still a surgical problem, and active autoimmune disease belongs with your rheumatologist first: regenerative therapy complements DMARDs and biologics rather than replacing them. Not FDA-approved for these uses; provided in México under COFEPRIS after individual physician review of your imaging, labs, and history.
